Co-Diagnostics (CODX) Q4 2025 earnings review
Pre-Commercial Pivot Hindered by Severe Cash Crunch and Massive Impairment
Co-Diagnostics is locked in a race against its own balance sheet. FY25 total revenue virtually evaporated to $0.6M as legacy grant funding dried up. Meanwhile, an $18.9M non-cash impairment charge on intangible assets drove the Q4 net loss to a staggering $25.7M (bringing FY25 net loss to $46.9M). The company ended the year with just $11.9M in cash, forcing highly dilutive pre-reverse split equity offerings. The entire investment case now rests on the delayed 2026 commercialization of its unapproved Co-Dx PCR platform, but the financial runway to get there is precariously short.
🐂 Bull Case
The company secured a crucial CDSCO license to manufacture and sell the CoSara PCR Pro instrument in India, unblocking a massive target market. The CoMira JV in Saudi Arabia is also finalizing its manufacturing facility.
Management is pivoting its FDA 510(k) strategy to initially focus on an upper respiratory multiplex test (Flu A/B and RSV), bypassing current COVID-19 enrollment hurdles and aiming for 2026 commercialization.
🐻 Bear Case
With an Adjusted EBITDA loss of $28.0M for FY25 and only $11.9M in cash at year-end, the company is entirely reliant on immediate, dilutive capital raises to fund basic operations.
An unexpected $18.9M impairment charge on intangible assets completely contradicts management's narrative of a strengthening intellectual property portfolio.
⚖️ Verdict: 🔴🔴
Highly Bearish. Despite optimistic timelines for 2026 commercialization, Co-Diagnostics is a pre-revenue company facing an acute liquidity crisis, forced dilution, and significant regulatory execution risk.
Key Themes
Massive Intangible Asset Impairment
An $18.9M non-cash impairment charge hit the Q4 income statement, completely Reversing the positive narrative around the company's IP strength. Intangible assets plunged from $26.1M in FY24 to just $7.2M. Management claims to be 'strengthening the intellectual property portfolio,' but this catastrophic write-down suggests historical R&D or past acquisitions have drastically lost commercial viability.
Severe Dilution to Bridge the Cash Gap
The cash burn trajectory is Accelerating relative to available funds. Adjusted EBITDA loss was $28.0M for FY25 against an ending cash balance of $11.9M. To survive, management closed two heavily dilutive offerings totaling $10.8M (at pre-reverse split prices of $0.40 and $0.55 per share). The company is funding long-term clinical trials with highly dilutive, short-term crisis capital.
Grant Revenue Collapse
Total revenue Decelerated violently, falling 84% from $3.9M in FY24 to just $0.6M in FY25. The core driver was the near-total evaporation of Grant Revenue, which sank from $3.1M to $0.2M. Because the company relies on grants to validate and partially fund its pipeline (like the NIH RADx program), this drop removes a critical non-dilutive financing pillar.
CoSara and CoMira Joint Ventures Localizing Distribution
The international footprint is a rare bright spot. The CoSara JV in India successfully obtained a CDSCO license to manufacture and sell the PCR Pro instrument—a mandatory step for commercialization. Furthermore, the commercial territory for CoSara was expanded to include Bangladesh, Pakistan, Nepal, and Sri Lanka, opening a $13 billion regional addressable market. Meanwhile, the CoMira JV in Saudi Arabia is finalizing a manufacturing lease.
Macro Realities Force Regulatory Pivot
A shift in the macro environment—specifically, dramatically reduced rates of COVID-19 prevalence—has forced management to change its regulatory strategy. Instead of pursuing a combined COVID test first, the initial FDA 510(k) submission will focus purely on an upper respiratory multiplex test (Flu A, Flu B, and RSV). COVID-19 testing capabilities will be incorporated at a later stage if conditions change.
Integration of Machine Learning into Primer Ai
The company expanded its newly formed AI business unit, actively integrating machine learning capabilities into the Co-Dx Primer Ai platform. This technological innovation is intended to streamline test design, automate analysis, and provide predictive epidemiological insights, theoretically creating a wider moat for their diagnostic ecosystem.
Other KPIs
Accelerating significantly from $43.0M in FY24. While day-to-day R&D and SG&A actually decreased slightly due to cost-control measures, the massive $18.9M non-cash impairment charge drove total operating expenses substantially higher, masking underlying cash preservation efforts.
Stable to slightly improving. Compared to a $33.5M loss in FY24, the company slightly narrowed its cash burn. However, when viewed against the $11.9M ending cash balance, this burn rate remains completely unsustainable without continuous capital injections.
Guidance
Management explicitly targets 2026 for the commercialization of the Co-Dx PCR platform. This implies at least 12-18 more months of cash burn, clinical trial execution, and regulatory waiting periods before meaningful product revenue can materialize.
Reversing its previous focus, the company guided that its initial FDA submission will drop COVID-19 from the panel due to lack of trial prevalence. Management claims this modified approach will accelerate regulatory timelines.
Key Questions
Details on the Intangible Impairment
You recorded an $18.9M impairment charge on intangible assets this quarter. Specifically, which assets, patents, or past acquisitions were written down, and how does this square with your claim of a strengthening IP portfolio?
Bridging the Cash Chasm
With an Adjusted EBITDA burn of $28M in FY25 and only $11.9M in cash on hand at year-end, what is the exact cash runway? How much additional dilution should current shareholders expect before the targeted 2026 commercialization?
Impact of the Dropped COVID Submission
By dropping COVID-19 from the initial 510(k) submission due to prevalence issues, how much time does this practically shave off your timeline? Furthermore, how does a non-COVID respiratory panel impact the expected pricing and market demand at launch?